Clinical Trial Detail

NCT ID NCT04128696
Title Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline

hypopharynx cancer

oral cavity cancer

laryngeal squamous cell carcinoma

oropharynx cancer

head and neck squamous cell carcinoma



GSK3359609 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.